UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): March
31, 2015
BioTime,
Inc.
(Exact name of registrant as specified in its charter)
California
|
1-12830
|
94-3127919
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Forward-Looking Statements
Any statements that are not historical fact (including, but not
limited to statements that contain words such as “may,” “will,”
“believes,” “plans,” “intends,” “anticipates,” “expects,” “estimates”)
should also be considered to be forward-looking statements. Additional
factors that could cause actual results to differ materially from the
results anticipated in these forward-looking statements are contained in
BioTime’s periodic reports filed with the Securities and Exchange
Commission (“SEC”) under the heading “Risk Factors” and other filings
that BioTime may make with the SEC. Undue reliance should not be placed
on these forward-looking statements which speak only as of the date they
are made, and the facts and assumptions underlying these statements may
change. Except as required by law, BioTime disclaims any intent or
obligation to update these forward-looking statements.
This Report and the accompanying Exhibit 99.1 shall be deemed
“furnished” and not “filed” under the Securities Exchange Act of 1934,
as amended.
Section 7 - Regulation FD
Item 7.01 - Regulation FD Disclosure
On March 31, 2015, we and our subsidiary LifeMap Solutions, Inc. issued
the press release furnished as Exhibits 99.1 to this report, which is
incorporated by reference.
Section 9 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits.
Exhibit Number
|
Description
|
99.1
|
Press release dated March 31, 2015
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
BIOTIME, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
March
31, 2015
|
By:
|
/s/ Michael D. West
|
|
|
|
|
Chief Executive Officer
|
Exhibit Number
|
Description
|
99.1
|
Press release dated March 31, 2015
|
Exhibit 99.1
LifeMap
Solutions and Mount Sinai – National Jewish Health Respiratory Institute
Launch Pilot Program of COPD Navigator App
App
for Patients is First Component of Broader Chronic-Condition Platform
that Integrates with “Smart” Inhaler Technology and Clinician Dashboard
SAN JOSE, Calif.--(BUSINESS WIRE)--March 31, 2015--LifeMap Solutions, an
emerging digital therapeutics provider and subsidiary of BioTime, Inc.
(NYSE MKT: BTX), today launched a pilot program for COPD Navigator, an
Apple HealthKit-compliant iOS app that helps patients monitor and manage
the symptoms of COPD. Developed in close partnership with researchers
from the Icahn School of Medicine at Mount Sinai and with COPD experts
from the Mount Sinai – National Jewish Health Respiratory Institute,
COPD Navigator harnesses the power of mHealth (mobile health) technology
and big data analysis to provide COPD patients with an engaging,
interactive coach in their pocket. A patient’s doctor specifies the
app’s settings and communications. During the pilot program, physicians
at The Respiratory Institute will work with patients who use the COPD
Navigator iPhone app with the goal of improving their self-management of
COPD.
“Chronic Obstructive Pulmonary Disease—COPD—is the third leading cause
of death in the US, and it affects an estimated 24 million Americans.
But patients can slow the progression of the disease and improve quality
of life through effective self-management,” said Corey Bridges, CEO of
LifeMap Solutions. “The promise of the mHealth revolution is to empower
patients with self-management tools that are engaging and easy to use.
COPD Navigator is the first product in our suite of chronic-condition
apps, which fulfill that promise.”
“We’ve worked with the LifeMap team to help them design an app that
leverages evidence-based care guidelines, behavioral science, and
patient data to deliver personalized information with the purpose of
achieving better outcomes at lower costs,” said Charles Powell, MD, CEO
of Mount Sinai – National Jewish Health Respiratory Institute. “As
physicians, our goals throughout product development were to help
LifeMap produce a product that integrates easily into a care team’s
workflow and to maximize benefit to patients.”
COPD Navigator: First Component of Disease Management Platform
COPD Navigator tracks patient data that includes symptoms, medication
and treatment adherence, and overall quality of life. This information
is presented in an easy-to-understand and configurable graph that
empowers the patient to recognize patterns in their own health history,
as well as to send this information to their doctor. Additionally, the
app helps patients avoid environmental risk factors by providing
real-time alerts about local air quality and extreme weather, and it
delivers educational content from leading respiratory hospital, National
Jewish Health.
The COPD Navigator app is the first component of LifeMap’s larger COPD
management platform, which also includes Bluetooth-enabled inhaler
technology and a clinician dashboard for care providers. Through its
support for Apple’s HealthKit technology, COPD Navigator accepts inhaler
usage information from any HealthKit-compliant, Bluetooth-enabled,
“smart” inhaler device. In the pilot program at Mount Sinai, LifeMap
Solutions is providing a smart device of its own design, allowing the
app to know automatically when the patient has used their inhaler. This
inhaler-usage information helps the app track medication adherence and
identify potential environmental and behavioral triggers of
exacerbations, which are episodes in which COPD symptoms suddenly get
much worse. Identifying trends and individual triggers can help patients
improve the overall quality of their health and avoid circumstances that
worsen their condition.
The other major component of LifeMap’s COPD platform, the clinician
dashboard for care providers, is a HIPAA-compliant tool that offers a
view of the health status of their patient populations. Providers can
also examine a specific patient’s record to see that patient’s care plan
adherence and symptoms over time. They can flag high-risk patients, set
rules for events-based alerts, and intervene early with the goal of
reducing the risk of acute exacerbations. The clinician dashboard also
enables care providers to send health alerts and reminders to their
patients.
Leveraging Big Data to Unlock New Findings
As part of the company’s partnership with the Icahn School of Medicine
at Mount Sinai, LifeMap Solutions is working with the Icahn Institute
for Genomics and Multiscale Biology to provide unprecedented amounts of
secure, anonymized data to facilitate ongoing research into COPD and
other medical conditions. The team plans to use this data to develop
algorithms for predicting exacerbations, identifying effective
interventions, and personalizing care plans based on demographics,
lifestyle, and clinical history. In addition to COPD Navigator, LifeMap
Solutions plans to release more apps to address other chronic diseases
in the near future.
“The analysis of the health outcomes and data captured from mHealth apps
and devices informs the development of an expanded disease management
platform,” said Eric Schadt, PhD, Director of the Icahn Institute for
Genomics and Multiscale Biology at Mount Sinai. “This platform provides
a comprehensive solution for treatment of chronic diseases, including
further opportunities for clinician engagement with patients.”
The COPD Navigator app is expected to be commercially available in the
second half of 2015.
About LifeMap Solutions, Inc.
LifeMap Solutions is developing innovative digital therapeutics in
partnership with the Icahn Institute for Genomics and Multiscale
Biology, which is located within the Icahn School of Medicine at Mount
Sinai. LifeMap digital therapeutic solutions integrate health and
wellness information with care team guidance into a secure mHealth
platform that empowers the patient to make better choices to achieve
optimal health outcomes. LifeMap Solutions is a subsidiary of BioTime,
Inc. LifeMap Solutions is headquartered in San Jose, California.
For more information, please visit www.lifemap-solutions.com.
About Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed
to providing distinguished care, conducting transformative research, and
advancing biomedical education. Structured around seven member hospital
campuses and a single medical school, the Health System has an extensive
ambulatory network and a range of inpatient and outpatient services from
community-based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care
physicians, 12 minority-owned free-standing ambulatory surgery centers,
over 45 ambulatory practices throughout the five boroughs of New York
City, Westchester, and Long Island, as well as 31 affiliated community
health centers. Physicians are affiliated with the Icahn School of
Medicine at Mount Sinai, which is ranked among the top 20 medical
schools both in National Institutes of Health funding and by U.S. News &
World Report.
For more information, visit http://www.mountsinai.org, or find
Mount Sinai on Facebook, Twitter and YouTube.
About Mount Sinai – National Jewish Respiratory Health Institute
The Icahn School of Medicine at Mount Sinai, a top-ranked academic
medical center in New York City, and National Jewish Health, the
nation’s leading respiratory hospital based in Denver, Colorado, have
partnered to create the Mount Sinai – National Jewish Health Respiratory
Institute. Combining the strengths of both entities into an integrated
Respiratory Institute brings together leading expertise in diagnosing
and treating all forms of respiratory illness and lung disease,
including asthma, chronic obstructive pulmonary disease (COPD),
interstitial lung disease (ILD) and bronchiectasis. The Respiratory
Institute creates new options for patients in New York City and the
surrounding region. Through the integration of research advances,
clinical skill and patient-focused processes and protocols, the
Respiratory Institute offers a model for the state-of-the-art delivery
of multidisciplinary, outcomes-driven care, and for the application of
personalized medicine for the treatment of respiratory disease.
For more information, please visit: http://therespiratoryinstitute.org/.
About BioTime, Inc.
BioTime, Inc., a pioneer in regenerative medicine, is a clinical-stage
biotechnology company. BioTime and its subsidiaries are leveraging their
industry-leading experience in pluripotent stem cell technology and a
broad intellectual property portfolio to facilitate the development and
use of cell-based therapies and gene marker-based molecular diagnostics
for major diseases and degenerative conditions for which there presently
are no cures. The lead clinical programs of BioTime and its subsidiaries
include: OpRegen®, currently in a Phase
I/IIa trial for the treatment of the dry form of age-related macular
degeneration; AST-OPC1, currently in a Phase I/IIa trial for
spinal cord injuries; Renevia™, currently in a pivotal trial in
Europe as an injectable matrix for the engraftment of transplanted cells
to treat HIV-related lipoatrophy; and PanC-Dx™ cancer
diagnostics, which are completing initial clinical studies for bladder,
breast, and lung cancer. AST-VAC2, a cancer vaccine, is in
the pre-clinical trial stage.
BioTime’s subsidiaries include: publicly-traded Asterias
Biotherapeutics, Inc. (NYSE MKT: AST), developing pluripotent stem
cell-based therapies in neurology and oncology, including AST-OPC1
and AST-VAC2; Cell Cure Neurosciences Ltd., developing stem
cell-based therapies for retinal and neurological disorders, including OpRegen®;
OncoCyte Corporation, developing PanC-Dx™ cancer diagnostics;
LifeMap Sciences, Inc., developing and marketing an integrated on-line
database resource for biomedical and stem cell research; LifeMap
Solutions, Inc., a subsidiary of LifeMap Sciences, developing mobile
health (mHealth) products; ES Cell International Pte Ltd, which has
developed cGMP compliant human embryonic stem cell lines that are being
marketed by BioTime for research purposes under the ESI BIO branding
program; OrthoCyte Corporation, developing therapies to treat orthopedic
disorders, diseases and injuries; and ReCyte Therapeutics, Inc.,
developing therapies to treat a variety of cardiovascular and related
ischemic disorders.
For more information, please visit: www.biotimeinc.com.
CONTACT:
Media Relations Contacts
TriplePoint for LifeMap
Solutions
415-955-8500
lifemap@triplepointpr.com
or
BioTime,
Inc.
Judith Segall, 510-521-3390 ext. 301
jsegall@biotimemail.com
or
Gotham
Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024